Inactive Instrument

Neuropathix, Inc.

Equities

NPTX

US64132Q1094

Biotechnology & Medical Research

Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

November 13, 2021 at 12:46 am IST

Neuropathix, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.721333 million compared to USD 0.610806 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the nine months, revenue was USD 0.067 million. Net loss was USD 2.8 million compared to USD 2.98 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago.

Latest news about Neuropathix, Inc.

Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/22/24	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Neuropathix, Inc. announced that it has received $0.15 million in funding	21/22/21	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	13/21/13	CI
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	12/21/12	CI
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	06/21/06	CI
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	31/21/31	CI
Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	10/21/10	CI
Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	12/21/12	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	12/20/12	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	06/20/06	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	05/20/05	CI
Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of Advisors	17/20/17	CI
Kannalife, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	13/20/13	CI
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories	09/20/09	CI
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors	02/20/02	CI
Kannalife, Inc. announced that it expects to receive $0.156 million in funding	02/20/02	CI
Kannalife, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	14/20/14	CI
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD	14/20/14	CI
Kannalife, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	31/20/31	CI
Kannalife, Inc. announced that it expects to receive $0.2 million in funding	12/20/12	CI
Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent	20/20/20	CI
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN	11/20/11	CI

Chart Neuropathix, Inc.

Duration

Period

More charts

Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs